Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.33 |
| ▸ | LPL | P06858 | 7/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2068803 | 0.81 | APP (0.39) | PDGFRBKDRFFAR1DGAT1GSK3A | |
| SCHEMBL12537221 | 0.81 | DGAT1 (0.42) | PDGFRBKDRDGAT1GSK3AGSK3B | |
| SCHEMBL7862710 | 0.81 | GRM2 (0.37) | FFAR1DGAT1GSK3AGSK3BLPL | |
| SCHEMBL720459 | 0.80 | PDGFRB (0.37) | PDGFRBKDRFFAR1DGAT1GSK3A | |
| SCHEMBL17149346 | 0.80 | LPL (0.36) | DGAT1GSK3AGSK3BLPLLIPG | |
| SCHEMBL15328732 | 0.79 | FFAR1 (0.41) | PDGFRBKDRFFAR1DGAT1GSK3A | |
| SCHEMBL16322931 | 0.78 | LPL (0.38) | MTNR1ALPLLIPGIRAK4 | |
| SCHEMBL1564459 | 0.78 | DGAT1 (0.37) | PDGFRBKDRFFAR1DGAT1GSK3A | |
| SCHEMBL12821571 | 0.77 | UCHL1 (0.43) | DGAT1 | |
| SCHEMBL17136838 | 0.76 | LIPE (0.38) | PDGFRBKDRLPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021465-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-06-01 | — | — | US | disclosed |
| US-11008305-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3459942-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2020-12-30 | — | — | EP | disclosed |
| CN-106977495-B | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20200109130-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-04-09 | — | — | US | disclosed |
| US-20200062732-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-02-27 | — | — | US | disclosed |
| CN-106986863-B | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2019-12-31 | — | — | CN | disclosed |
| US-10442791-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-10-15 | — | — | US | disclosed |
| US-10391095-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-27 | — | — | US | disclosed |
| EP-3459942-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2019-03-27 | — | — | EP | disclosed |
| US-9592232-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160368899-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160250212-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-09-01 | — | — | US | disclosed |
| EP-3057959-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2016-08-24 | — | — | EP | disclosed |
| US-9376448-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-28 | — | — | US | disclosed |
| US-9296701-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-03-29 | — | — | US | disclosed |
| WO-2015058031-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20150111871-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-04-23 | — | — | US | disclosed |
| US-20140045869-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-02-13 | — | — | US | disclosed |
| US-20130281431-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045869-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | PDGFRB 1566/4885KDR 1164/4885FFAR1 4725/4885 |
| US-20160368899-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | PDGFRB 1566/4885KDR 1164/4885FFAR1 4725/4885 |
| US-20200109130-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | PDGFRB 1566/4885KDR 1164/4885FFAR1 4725/4885 |
| US-20160250212-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | PDGFRB 1566/4885KDR 1164/4885FFAR1 4725/4885 |
| US-11008305-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PDGFRB 1566/4885KDR 1164/4885FFAR1 4725/4885 |
| US-20150111871-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | PDGFRB 1566/4885KDR 1164/4885FFAR1 4725/4885 |
| US-10442791-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PDGFRB 1566/4885KDR 1164/4885FFAR1 4725/4885 |
| US-20200062732-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | PDGFRB 1566/4885KDR 1164/4885FFAR1 4725/4885 |
| US-20130281431-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | PDGFRB 1566/4885KDR 1164/4885FFAR1 4725/4885 |
| US-10391095-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PDGFRB 1566/4885KDR 1164/4885FFAR1 4725/4885 |
| US-11021465-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PDGFRB 1566/4885KDR 1164/4885FFAR1 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.